The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly]," Dr. Jay Bradner, executive vice president of research and development and chief scientific officer at drug maker Amgen, said in a company news release. "Imdelltra offers these patients who are in urgent need of new innovative therapies hope, and we're proud to deliver this long-awaited effective treatment to them.
In a company trial, tarlatamab tripled patients' life expectancy, giving them a median survival of 14 months. But not everyone benefited: Forty percent of those who got the drug responded.] treatment landscape, there is now an effective and innovative treatment option available," Laurie Fenton Ambrose, co-founder, president and CEO of GO2 for Lungeffectiveness, it does have a serious side effect called a cytokine release syndrome, the FDA said.
had small cell lung cancer. After chemotherapy and immunotherapy, with her cancer still spreading rapidly, she was accepted into the Amgen study and began getting infusions of the drug.New York TimesLearn about lung cancer symptoms and treatments. Get more information on small cell lung cancer, non-small cell lung cancer, and the diagnosis of lung cancer stages.
Source: Healthcare Press (healthcarepress.net)
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: NBCNews - 🏆 10. / 86 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: MedicineNet - 🏆 575. / 51 Read more »
Source: ABC7 - 🏆 67. / 68 Read more »
Source: Health - 🏆 396. / 53 Read more »